146 related articles for article (PubMed ID: 31387830)
1. Fluorescence-guided bone resection: A histological analysis in medication-related osteonecrosis of the jaw.
Wehrhan F; Weber M; Neukam FW; Geppert CI; Kesting M; Preidl RHM
J Craniomaxillofac Surg; 2019 Oct; 47(10):1600-1607. PubMed ID: 31387830
[TBL] [Abstract][Full Text] [Related]
2. Histologic analysis of medication-related osteonecrosis of the jaw compared with antiresorptive-exposed bone and other infectious, inflammatory, and necrotic jaw diseases.
Yuan A; Munz A; Reinert S; Hoefert S
Oral Surg Oral Med Oral Pathol Oral Radiol; 2020 Feb; 129(2):133-140. PubMed ID: 31606424
[TBL] [Abstract][Full Text] [Related]
3. Fluorescence-guided surgery for the treatment of medication-related osteonecrosis of the jaw: A prospective cohort study.
Otto S; Ristow O; Pache C; Troeltzsch M; Fliefel R; Ehrenfeld M; Pautke C
J Craniomaxillofac Surg; 2016 Aug; 44(8):1073-80. PubMed ID: 27263757
[TBL] [Abstract][Full Text] [Related]
4. CT imaging features of antiresorptive agent-related osteonecrosis of the jaw/medication-related osteonecrosis of the jaw.
Baba A; Goto TK; Ojiri H; Takagiwa M; Hiraga C; Okamura M; Hasegawa S; Okuyama Y; Ogino N; Yamauchi H; Kobashi Y; Yamazoe S; Munetomo Y; Mogami T; Nomura T
Dentomaxillofac Radiol; 2018 May; 47(4):20170323. PubMed ID: 29365278
[TBL] [Abstract][Full Text] [Related]
5. Fluorescence-guided surgical management of medication-related osteonecrosis of the jaws.
Tomo S; da Cruz TM; Figueira JA; Cunha JLS; Miyahara GI; Simonato LE
Photodiagnosis Photodyn Ther; 2020 Dec; 32():102003. PubMed ID: 32916330
[TBL] [Abstract][Full Text] [Related]
6. Medication-related osteonecrosis of the jaw: Osteoclast profile in comparison with osteoradionecrosis of the jaw and osteomyelitis of the jaw.
Ngoc Thuy Tran V; Chaisuparat R
J Oral Pathol Med; 2021 Aug; 50(7):731-740. PubMed ID: 34038006
[TBL] [Abstract][Full Text] [Related]
7. Osteoclast profile of medication-related osteonecrosis of the jaw secondary to bisphosphonate therapy: a comparison with osteoradionecrosis and osteomyelitis.
Gross C; Weber M; Creutzburg K; Möbius P; Preidl R; Amann K; Wehrhan F
J Transl Med; 2017 Jun; 15(1):128. PubMed ID: 28587628
[TBL] [Abstract][Full Text] [Related]
8. Biologic and pathologic aspects of osteocytes in the setting of medication-related osteonecrosis of the jaw (MRONJ).
Aguirre JI; Castillo EJ; Kimmel DB
Bone; 2021 Dec; 153():116168. PubMed ID: 34487892
[TBL] [Abstract][Full Text] [Related]
9. Differences between auto-fluorescence and tetracycline-fluorescence in medication-related osteonecrosis of the jaw-a preclinical proof of concept study in the mini-pig.
Ristow O; Nehrbass D; Zeiter S; Arens D; Moratin J; Pautke C; Hoffmann J; Freudlsperger C; Otto S
Clin Oral Investig; 2020 Dec; 24(12):4625-4637. PubMed ID: 32444918
[TBL] [Abstract][Full Text] [Related]
10. Fluorescence-guided bone resection in bisphosphonate-related osteonecrosis of the jaws: first clinical results of a prospective pilot study.
Pautke C; Bauer F; Otto S; Tischer T; Steiner T; Weitz J; Kreutzer K; Hohlweg-Majert B; Wolff KD; Hafner S; Mast G; Ehrenfeld M; Stürzenbaum SR; Kolk A
J Oral Maxillofac Surg; 2011 Jan; 69(1):84-91. PubMed ID: 20971542
[TBL] [Abstract][Full Text] [Related]
11. Intraoperative efficiency of fluorescence imaging by Visually Enhanced Lesion Scope (VELscope) in patients with bisphosphonate related osteonecrosis of the jaw (BRONJ).
Assaf AT; Zrnc TA; Riecke B; Wikner J; Zustin J; Friedrich RE; Heiland M; Smeets R; Gröbe A
J Craniomaxillofac Surg; 2014 Jul; 42(5):e157-64. PubMed ID: 24011463
[TBL] [Abstract][Full Text] [Related]
12. Osteoclastic expression of higher-level regulators NFATc1 and BCL6 in medication-related osteonecrosis of the jaw secondary to bisphosphonate therapy: a comparison with osteoradionecrosis and osteomyelitis.
Wehrhan F; Gross C; Creutzburg K; Amann K; Ries J; Kesting M; Geppert CI; Weber M
J Transl Med; 2019 Mar; 17(1):69. PubMed ID: 30832685
[TBL] [Abstract][Full Text] [Related]
13. Intraoperative detection of viable bone with fluorescence imaging using Visually Enhanced Lesion Scope in patients with bisphosphonate-related osteonecrosis of the jaw: clinical and pathological evaluation.
Yoshiga D; Sasaguri M; Matsuo K; Kokuryou S; Habu M; Oda M; Kodama M; Tsurushima H; Sakaguchi O; Sakurai T; Tanaka J; Morimoto Y; Yoshioka I; Tominaga K
Osteoporos Int; 2015 Jul; 26(7):1997-2006. PubMed ID: 26037792
[TBL] [Abstract][Full Text] [Related]
14. Clinical Differences in Autofluorescence Between Viable and Nonvital Bone: A Case Report With Histopathologic Evaluation Performed on Medication-Related Osteonecrosis of the Jaws.
Giovannacci I; Meleti M; Corradi D; Vescovi P
J Oral Maxillofac Surg; 2017 Jun; 75(6):1216-1222. PubMed ID: 28061356
[TBL] [Abstract][Full Text] [Related]
15. The Therapeutic Effectiveness Using Fluorescence-Guided Surgery for MRONJ.
Huang H; Zhao N; Li Q; Qiao Q; Zhang J; Guo C; Guo Y
Biomed Res Int; 2022; 2022():1650790. PubMed ID: 36164452
[TBL] [Abstract][Full Text] [Related]
16. Fluorescence-guided bone resection in bisphosphonate-associated osteonecrosis of the jaws.
Pautke C; Bauer F; Tischer T; Kreutzer K; Weitz J; Kesting M; Hölzle F; Kolk A; Stürzenbaum SR; Wolff KD
J Oral Maxillofac Surg; 2009 Mar; 67(3):471-6. PubMed ID: 19231768
[TBL] [Abstract][Full Text] [Related]
17. Auto-fluorescence of the bone and its use for delineation of bone necrosis.
Ristow O; Pautke C
Int J Oral Maxillofac Surg; 2014 Nov; 43(11):1391-3. PubMed ID: 25128260
[TBL] [Abstract][Full Text] [Related]
18. Treatment perspectives for medication-related osteonecrosis of the jaw (MRONJ).
Ristow O; Otto S; Troeltzsch M; Hohlweg-Majert B; Pautke C
J Craniomaxillofac Surg; 2015 Mar; 43(2):290-3. PubMed ID: 25541255
[TBL] [Abstract][Full Text] [Related]
19. Efficacy of bovine lactoferrin in the post-surgical treatment of patients suffering from bisphosphonate-related osteonecrosis of the jaws: an open-label study.
Calvani F; Cutone A; Lepanto MS; Rosa L; Valentini V; Valenti P
Biometals; 2018 Jun; 31(3):445-455. PubMed ID: 29435826
[TBL] [Abstract][Full Text] [Related]
20. Tetracycline bone fluorescence: a valuable marker for osteonecrosis characterization and therapy.
Pautke C; Bauer F; Bissinger O; Tischer T; Kreutzer K; Steiner T; Weitz J; Otto S; Wolff KD; Stürzenbaum SR; Kolk A
J Oral Maxillofac Surg; 2010 Jan; 68(1):125-9. PubMed ID: 20006166
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
